- Home
- PHAR vs BTO Comparison
PHAR vs BTO Comparison
Compare PHAR & BTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- BTO
- Stock Information
- Founded
- PHAR 1988
- BTO 1994
- Country
- PHAR Netherlands
- BTO United States
- Employees
- PHAR N/A
- BTO N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- BTO Investment Managers
- Sector
- PHAR Health Care
- BTO Finance
- Exchange
- PHAR Nasdaq
- BTO Nasdaq
- Market Cap
- PHAR 718.1M
- BTO 670.7M
- IPO Year
- PHAR N/A
- BTO N/A
- Fundamental
- Price
- PHAR $11.24
- BTO $33.97
- Analyst Decision
- PHAR Strong Buy
- BTO
- Analyst Count
- PHAR 3
- BTO 0
- Target Price
- PHAR $30.00
- BTO N/A
- AVG Volume (30 Days)
- PHAR 3.1K
- BTO 54.2K
- Earning Date
- PHAR 05-08-2025
- BTO 01-01-0001
- Dividend Yield
- PHAR N/A
- BTO 9.13%
- EPS Growth
- PHAR N/A
- BTO N/A
- EPS
- PHAR N/A
- BTO N/A
- Revenue
- PHAR $320,708,000.00
- BTO N/A
- Revenue This Year
- PHAR $13.31
- BTO N/A
- Revenue Next Year
- PHAR $7.68
- BTO N/A
- P/E Ratio
- PHAR N/A
- BTO N/A
- Revenue Growth
- PHAR 24.13
- BTO N/A
- 52 Week Low
- PHAR $6.65
- BTO $22.95
- 52 Week High
- PHAR $11.07
- BTO $32.81
- Technical
- Relative Strength Index (RSI)
- PHAR 69.87
- BTO 50.02
- Support Level
- PHAR $10.02
- BTO $33.25
- Resistance Level
- PHAR $10.89
- BTO $34.47
- Average True Range (ATR)
- PHAR 0.23
- BTO 0.46
- MACD
- PHAR 0.11
- BTO -0.11
- Stochastic Oscillator
- PHAR 100.00
- BTO 14.68
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About BTO John Hancock Financial Opportunities Fund
John Hancock Financial Opportunities Fund is the United States based closed-end, diversified management investment company. Its investment objective is to provide a high level of total return consisting of long-term capital appreciation and current income. The company invests in banks, capital markets, Insurance, Mortage Real Estate Investment trust, Health Care REITs, Diversified REITs, Office REITs.